Results 101 to 110 of about 325,639 (307)

NPM1 Mediates mRNA Sorting into Extracellular Vesicles via Specific RNA Motif Binding and Phase Separation

open access: yesAdvanced Science, EarlyView.
NPM1 selectively sorts specific mRNAs into extracellular vesicles (EVs) by recognizing RNA motifs and forming phase‐separated condensates. These mRNA cargos—including EGFR—are then loaded via multivesicular bodies. This active sorting pathway, validated in EVs derived from both lung cancer cells and patient serum, reveals a specific mechanism for ...
Kaixiang Zhang   +8 more
wiley   +1 more source

Pan-squamous genomic profiling stratified by anatomic tumor site and viral association [PDF]

open access: yes, 2018
Background: Squamous cell carcinomas (SCC) have diverse anatomic etiologies but may share common genomic biomarkers. We profiled 7,871 unique SCCs across nine anatomic sites to investigate commonality in genomic alterations (GA), tumor mutational burden (
Albacker, L. A.   +10 more
core   +1 more source

Cuproptosis and Disulfidptosis Converge to Empower PD‐L1 Checkpoint Therapy via Cadict‐Induced PD‐L1 Translation

open access: yesAdvanced Science, EarlyView.
This study introduces Cadict, an EGFR‐targeted nanodrug that co‐delivers cuproptosis and disulfidptosis inducers to overcome immune resistance. Cadict synergistically enhances tumor cytotoxicity and sensitizes cancers to ICIs by upregulating PD‐L1 via an Eif5b‐dependent translation mechanism, fostering a potent antitumor immune response and ...
Shaoqing Huang   +12 more
wiley   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

open access: yesAdvanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong   +5 more
wiley   +1 more source

Epidermal growth factor receptor mutant T790M-L858R-V948R inhibitor from Calophyllum inophyllum L. leaf as potential non-small cell lung cancer drugs [PDF]

open access: yesJournal of Pharmacy & Pharmacognosy Research
Context: Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer type, with 80-85% prevalence. Usually, NSCLC is treated by chemotherapy and radiotherapy in collaboration with gefitinib or other anticancer drugs.
Precella Silvia   +2 more
doaj   +1 more source

Deep Learning‐Powered Scalable Cancer Organ Chip for Cancer Precision Medicine

open access: yesAdvanced Science, EarlyView.
This scalable, low‐cost Organ Chip platform, made via injection molding, uses capillary pinning for hydrogel confinement and supports versatile tissue coculture and robust imaging. Deep learning enables label‐free, sensitive phenotypic analysis.
Yu‐Chieh Yuan   +24 more
wiley   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

open access: yesAdvanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu   +11 more
wiley   +1 more source

Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies. [PDF]

open access: yes, 2012
BackgroundThe advent of personalized medicine requires robust, reproducible biomarkers that indicate which treatment will maximize therapeutic benefit while minimizing side effects and costs.
Boutros, Paul C   +8 more
core   +2 more sources

DMAP1 Deficiency Suppresses Lung Cancer Progression by Destabilizing Replication Fork and Activating IFN Signaling‐Mediated Anti‐tumor Immunity

open access: yesAdvanced Science, EarlyView.
Lung cancer remains the leading cause of cancer‐related death. We investigated the role of the epigenetic regulator DMAP1 in NSCLC and found that its loss induces replication stress and DNA damage. This in turn activates type I IFN signaling via the cGAS–STING pathway and transcriptional ISG de‐repression, enhancing anti‐tumor immune responses ...
Kan Huang   +10 more
wiley   +1 more source

The AUTACE That Degrades KRAS and Engages CD8+ T Cells for the Treatment of KRAS/TP53 Co‐Mutant Tumors

open access: yesAdvanced Science, EarlyView.
AUTACE is a bifunctional nanoplatform that integrates tumor targeting, immune engagement, and on‐demand KRAS degradation. It targets KRAS/TP53 co‐mutant tumors via TP53‐specific TCRs, elicits antitumor CD8+ T‐cell responses through surface anti‐CD3 antibodies, and uses low‐intensity focused ultrasound (LIFU) to trigger controlled release of the KRAS ...
Luo Li   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy